Maintenance therapy after CAR-T for low-risk B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have B-cell non-Hodgkin lymphoma that has come back or not responded to at least one prior treatment.
- You have never had CAR-T cell therapy before.
- You have never had a stem cell transplant from a donor.
- Your heart, kidneys, and liver are working well enough for the treatment.
- You do not have a serious active infection, uncontrolled diabetes, or a recent other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that uses a drug called ARTA (a special type of therapy) instead of chemotherapy to help prepare for and maintain CAR-T cell treatment in people with aggressive B-cell lymphoma that has returned or not responded to previous treatments, and who are not able to have a stem cell transplant.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This study tests if taking zanubrutinib (a pill) after CAR-T cell therapy helps keep non-Hodgkin B-cell lymphoma from coming back. It is for people who have already had or will have CAR-T treatment and can continue with this oral medication as a maintenance step.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
Hear when a new B-NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.